Pfiz­er wins first US ap­proval for pen­tava­lent meningo­coc­cal vac­cine 

Pfiz­er on Fri­day won ap­proval for its next mass-mar­ket vac­cine, a pen­tava­lent meningo­coc­cal vac­cine cov­er­ing the most com­mon serogroups in­fect­ing chil­dren and young adults ages 10 to 25 years old.

The vac­cine, dubbed Pen­braya, com­bines the com­po­nents of Pfiz­er’s two cur­rent­ly ap­proved vac­cines Tru­men­ba and Ni­men­rix, to­geth­er cov­er­ing groups A, B, C, W and Y. Meningo­coc­cal dis­ease can cause menin­gi­tis, or in­flam­ma­tion of the brain and spinal cord mem­branes.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.